NEW YORK, Oct. 17, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ('Seelos'), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has retained Canaccord Genuity to assist in its ongoing review of potential partnerships, collaborations, and similar opportunities..

纽约，2023年10月17日/PRNewswire/-Seelos Therapeutics，Inc。（纳斯达克股票代码：SEEL）（'Seelos'），一家临床阶段生物制药公司，专注于开发中枢神经系统疾病和罕见疾病的治疗方法，今天宣布，它保留了加拿大的力量，以协助其持续审查潜在的伙伴关系，合作和类似机会。。

There can be no assurance that the review process will result in the entry into any partnerships, collaborations, or other transactions, or as to the timing of any of the foregoing. Seelos does not expect to comment further on this review unless and until its Board of Directors has approved a specific course of action or until it determines that further disclosure is appropriate or required by law..

不能保证审查过程将导致进入任何伙伴关系，合作或其他交易，或关于上述任何一项的时间。除非并且直到其董事会批准了特定的行动方案或直到其确定进一步的披露是适当的或法律要求，否则Seelos不希望对此评论作进一步评论。。

About Seelos Therapeutics

关于Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington's disease, Alzheimer's disease, and Parkinson's disease..

Seelos Therapeutics，Inc.是一家临床阶段的生物制药公司，致力于开发和开发新型疗法，以满足未满足的医疗需求，从而为中枢神经系统（CNS）疾病和其他罕见疾病患者带来益处。该公司强大的投资组合包括针对严重抑郁症（MDD），肌萎缩侧索硬化症（ALS）和脊髓小脑性共济失调（SCA）等急性自杀意念和行为（ASIB）以及亨廷顿舞蹈病，阿尔茨海默病和帕金森病。。

For more information, please visit our website: https://seelostherapeutics.com, the content of which is not incorporated herein by reference.

欲了解更多信息，请访问我们的网站：https://seelostherapeutics.com，其内容未通过引用并入本文。

Forward Looking Statements

前瞻性声明

Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding the ongoing review of potential partnership or collaboration opportunities and potential other transactions, as well as the potential timing of any such transaction.

本新闻稿中所作的声明本质上不是历史性的，构成了1995年“私人证券诉讼改革法”提供的安全港的前瞻性声明。这些声明除其他外还包括关于正在进行的潜在合伙关系或合作机会以及潜在其他交易审查的声明，以及任何此类交易的潜在时机。

These statements are based on Seelos' current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated with Seelos' business and plans described herein include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies, not being able to move forward with the development of any of its product candidates, and not gaining marketing approvals for any of its product candidates; the risk that prior clinical results may not be replicated in future studies and trials (including the risk that the results from the prior studies of its product candidates may not be replicated or may be materially different from the results of the preclinical data or other studies); the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; the risks associated with the implementation of Seelos' business strategy; the risks related to raising capital to fund its development plans and ongoing operations; the risks related to Seelos' current stock price; as well as other factors expressed in Seelos' periodic filings with the U.S.

这些陈述基于Seelos目前的预期和信念，并受到许多风险和不确定性的影响，可能导致实际结果与前瞻性陈述中描述的结果大不相同。与本文所述的Seelos业务和计划相关的风险包括但不限于未成功执行其临床前和临床研究的风险，无法随着其任何候选产品的开发而前进，并且未获得市场任何产品候选人的批准；在未来的研究和试验中可能无法复制先前临床结果的风险（包括其产品候选物的先前研究结果可能无法复制或可能与临床前数据或其他研究结果有实质性差异的风险））；临床研究结果可能不符合临床研究的任何或所有终点以及此类研究产生的任何数据可能不支持监管机构提交或批准的风险；与实施Seelos业务战略相关的风险；筹集资金以资助其发展计划和持续运营的风险；与Seelos当前股票价格有关的风险；以及Seelos与美国定期提交的其他因素。

Securities and Exchange Comm.

证券交易通讯。

Contact Information:

联系方式：

Anthony MarcianoChief Communications OfficerSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Avenue, 2nd FloorNew York, NY 10022(646) 293-2136[email protected]https://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos

Anthony MarcianoChief Communications OfficerSeelos Therapeutics, Inc. (Nasdaq: SEEL)300 Park Avenue, 2nd FloorNew York, NY 10022(646) 293-2136[email protected]https://seelostherapeutics.com/https://twitter.com/seelostxhttps://www.linkedin.com/company/seelos

Mike MoyerManaging DirectorLifeSci Advisors, LLC250 West 55th St., Suite 3401New York, NY 10019(617) 308-4306mmoyer@lifesciadvisors.com

Mike Moyermangering DirectorLifeSci Advisors，LLC250 West 55th St.，Suite 3401New York，NY 10019（617）308-4306mmoyer@lifesciadvisors.com

SOURCE Seelos Therapeutics, Inc.

资料来源Seelos Therapeutics，Inc。